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ABSTRACT
Introduction: A non-interventional, multicen-
ter, European, prospective evaluation of the
effectiveness, tolerability, and safety of a topical
preservative-free tafluprost (0.0015%) and
timolol (0.5%) fixed-dose combination (PF
tafluprost/timolol FC) in adults with open-angle
glaucoma (OAG) and ocular hypertension
(OHT) demonstrating insufficient response to
topical beta-receptor blockers or prostaglandin
analogue (PGA) monotherapy.
Methods: Mean intraocular pressure (IOP)
change from baseline was measured at study
visits following a switch to PF tafluprost/timolol
FC. Primary endpoint was absolute mean IOP
change at month 6. Change from baseline
concerning ocular signs and symptoms was also
explored.
Results: Analyses included 577 patients (59.6%
female). Mean age (SD) was 67.8 (11.67) years.
Mean (SD) IOP reduction from baseline was sig-
nificant at all study visits; 5.4 (3.76) mmHg
(23.7%) at week 4, 5.9 (3.90) mmHg (25.6%) at
week 12, and 5.7 (4.11) mmHg (24.9%) at
month 6 (p\ 0.0001 for all visits). At month 6,
69.2%, 53.6%, 40.0%, and 25.8% were respon-
ders based on C 20%,C 25%, C 30%, and C 35%
cutoff values for mean IOP, respectively. Signifi-
cant reductions were observed concerning cor-
neal fluorescein staining (p\0.0001), dry eye
symptoms, irritation, itching, and foreign body
sensation (p\0.001 for each parameter). Con-
junctival hyperemia was significantly reduced at
all study visits (p\ 0.0001 at each visit). Overall,
69 treatment-related adverse events (AEs) were
reported, one of which was serious (status asth-
maticus). Most AEs were mild to moderate in
severity, and the majority had resolved or were
resolving at the end of the study period.
Conclusion: In clinical practice, PF
tafluprost/timolol FC provided statistically and
clinically significant IOP reductions in patients
with OAG and OHT insufficiently controlled on
or intolerant to PGA or beta-receptor blocker
monotherapy. The full IOP reduction appeared
at week 4 and was maintained over the 6-month
study period. Key symptoms of ocular surface
health improved.
Trial Registration: European Union electronic
Register of Post-Authorisation Studies (EU PAS)
register number, EUPAS22204.
The members of The VISIONARY Study Group are listed
in Acknowledgements.
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Key Summary Points
Why carry out this study?
Prostaglandin analogue (PGA) and beta-
receptor blocker combination therapies
are among the most extensively used
intraocular pressure (IOP)-lowering
treatments in glaucoma care. Fixed-dose
combinations simplify the treatment
regimen and reduce the number of daily
instillations, compared with
administration of the corresponding
concomitant medications, and
preservative-free formulations are
generally considered to offer improved
tolerability.
The VISIONARY study aimed to provide
real-world data concerning the treatment
effectiveness of the preservative-free
tafluprost (0.0015%) and timolol (0.5%)
fixed-dose combination (PF
tafluprost/timolol FC) in people with
open-angle glaucoma (OAG) and ocular
hypertension (OHT) who demonstrated
an insufficient response to previous
monotherapy treatment with topical beta-
receptor blocker or PGA monotherapy.
What was learned from the study?
Mean (SD) IOP reduction from baseline for
patients switched to PF tafluprost/timolol FC
from PGA or timolol therapy was 5.4 (3.76)
mmHg (23.7%) at week 4, 5.9 (3.90) mmHg
(25.6%) at week 12 and 5.7 (4.11) mmHg
(24.9%) at month 6 (p\0.0001 for all visits).
In routine clinical practice, PF
tafluprost/timolol FC provided statistically
and clinically significant IOP reduction
already at week 4, and the efficacy was
maintained over 6 months in patients with
OAG and OHT insufficiently controlled on
PGAs or beta-receptor blockers.
Key symptoms of ocular surface health
were improved, compared with previous
PGA or beta-receptor blocker
monotherapy, and treatment was
generally well tolerated.
INTRODUCTION
Elevated intraocular pressure (IOP) is the most
important modifiable risk factor for develop-
ment and progression of open-angle glaucoma
(OAG) [1]. A wealth of data has demonstrated
that IOP reduction is associated with slowing of
disease progression and visual field impairment;
IOP reduction is thus essential for the preser-
vation of vision in glaucoma [1–5].
Topical IOP-lowering medication remains
the mainstay of glaucoma therapy [1–5]. Strong
IOP-lowering efficacy, a simplified instillation
regimen, and good topical and systemic toler-
ance are all essential for optimal treatment
outcomes and long-term adherence with topical
glaucoma medications [6, 7]. When monother-
apies do not reach the target IOP, combination
therapy is necessary [6]. Prostaglandin analogue
(PGA) and beta-receptor blocker (typically
timolol 0.5%) combination therapies are among
the most extensively used medications in glau-
coma care [6, 8]. Fixed-dose combination (FC)
formulations are frequently used in preference
to the administration of the corresponding
concomitant medications, since they simplify
the treatment regimen and reduce the number
of daily instillations as well as the total amount
of preservatives applied to the eye
[1, 6, 7, 9–11].
Preservative-free (PF) topical glaucoma ther-
apy has become increasingly used in the man-
agement of glaucoma worldwide [7, 10–18].
Preservatives, and in particular benzalkonium
chloride (BAK), the most commonly used
preservative, have been shown to induce and
seriously worsen ocular surface disease (OSD)
[7, 19–24]. Preservative-induced OSD is a major
problem in the long-term topical treatment of
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glaucoma, affecting 45–60% of chronically
treated glaucomatous eyes [7, 25, 26]. PF medi-
cation is potentially advantageous for all glau-
comatous eyes because the BAK-induced ocular
surface toxicity worsens with the duration of
preserved topical treatment [7, 19–27]. The
overall quantity of BAK used throughout a
patient’s lifetime is also inversely related to fil-
tration surgery success [7, 19–27]. The fixed
combination of tafluprost 0.0015% and timolol
0.5% was one of the first PF PGA/timolol FCs
used for the treatment of OAG and ocular
hypertension (OHT) [10, 14–18]. Randomized
controlled trials demonstrated a low rate of
conjunctival hyperemia with PF tafluprost/ti-
molol FC treatment [14, 15]. A recent 24-h
investigation also showed that PF tafluprost/ti-
molol FC was associated with less frequent and
less severe hyperemia compared with the pre-
study period on preserved latanoprost treat-
ment [10].
Randomized, prospective, controlled inves-
tigations remain the gold standard for robust
assessment of efficacy and safety data for regu-
latory purposes. However, as a result of their
inclusion and exclusion criteria, the full spec-
trum of routine clinical practice cannot be
explored in such investigations. Regarding
topical glaucoma medications, observational
studies may provide additional information on
tolerance and real-life effectiveness since these
investigations also report on patients with OSD
or other relevant comorbidities that represent
exclusion criteria in most randomized,
prospective, clinical studies. In addition, obser-
vational studies reflect real-world experience
concerning medication change without prior
treatment washout. Therefore, real-world evi-
dence is becoming increasingly welcomed by
regulatory bodies [28–30].
In the current investigation, systematically
registered clinical data were used to evaluate the
IOP-lowering effectiveness and tolerability of
the PF tafluprost/timolol FC over a 6-month
period in participants with OAG and OHT, who
were previously treated with either a topical
PGA or a topical beta-receptor blocker
monotherapy.
METHODS
Study Design and Visit Schedule
This was a 6-month, observational, multicenter,
European, prospective clinical study. In line
with European Medicines Agency (EMA)
requirements, the study was registered under
the European Network of Centres for Pharma-
coepidemiology and Pharmacovigilance
(ENCePP) European Union electronic Register
of Post-Authorisation Studies (EU PAS Register)
(EU PAS register number EUPAS22204). The
study complied with the principles of the Dec-
laration of Helsinki. All patients included were
required to provide written informed consent
prior to their enrollment. The study protocol
was approved by the institutional review board
(IRB) or independent ethics committee (IEC) at
each center/institution. The study centers/in-
stitutions are listed in the Acknowledgments
alongside the relevant principal investigator.
Data were prospectively collected during
routine visits, between 10 April 2017 and 9
January 2019, at 66 ophthalmology clinics in
Austria, Denmark, Hungary, Ireland, Italy, Lat-
via, Netherlands, Norway, Russia, Spain, Swe-
den, and the UK. For patients, attendance was
mandatory only for the baseline and month 6
study visits. However, data were recorded dur-
ing interim study visits at week 4 and week 12
for participants who chose to attend these visits.
Baseline measures were recorded under
topical PGA or beta-receptor blocker medication
within 7 days prior to therapy change to PF
tafluprost/timolol FC. Variables were docu-
mented for each eye separately at baseline and
at study visits following initiation of PF
tafluprost/timolol FC treatment. Where data on
both eyes were available, the eye with the
higher baseline IOP value was selected for
analysis (study eye).
Patient Population
Male/female adult patients (aged C 18 years)
with a diagnosis of OAG or OHT were included
in the study. Participants had to be on a PGA or
a beta-receptor blocker monotherapy at time of
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inclusion. They had to have medically recorded
insufficient IOP control or poor tolerance on
the beta-receptor blocker or PGA monotherapy
prior to enrollment, which necessitated the use
of a combination therapy, and the patients had
to be considered likely to benefit from PF drops
formulation, according to the judgement of the
investigator ophthalmologist. It was possible for
the investigator to indicate more than one rea-
son for patient selection in the case report form.
The category of reasons for indicating PF
tafluprost/timolol FC comprised insufficient
IOP control or progression of glaucoma on the
current monotherapy, conversion of OHT to
OAG, poor local tolerance of the current topical
medication, insufficient adherence to the med-
ication used, or ‘‘other reasons’’.
The inclusion criteria required that the par-
ticipants had not undergone ophthalmic sur-
gery within 6 months prior to the study period
and had never received previous PF
tafluprost/timolol FC treatment. Patients who
were pregnant or breastfeeding at the screening
visit and those with any contraindication
against tafluprost or timolol treatment accord-
ing to the approved licensed indication and the
summary of product characteristics were not
allowed to enter the study.
Treatment
During the 6-month study period, the partici-
pants treated their affected eye(s) with PF
tafluprost/timolol FC (one drop daily, instilled
either in the morning or in the evening). The
instillation time (morning or evening) was
recorded at all study visits.
Efficacy Variables
The primary endpoint was absolute mean IOP
change from baseline at month 6, following the
initiation of PF tafluprost/timolol FC treatment,
measured with Goldmann applanation tonom-
etry in accordance with routine clinical practice
[6]. Secondary endpoints comprised mean IOP
change from baseline at interim visits, respon-
der rate, change in clinical signs, and severity of
subjective symptoms.
Responders were defined as patients with IOP
change from baseline of 20% or more at
week 12. In addition, the responder rate was
also explored at week 4 and month 6. Other
cutoff points for change in mean IOP that were
explored at week 4, week 12, and month 6
comprised 25%, 30%, and 35%.
Subanalyses of IOP data comprised mean IOP
change from baseline according to the diag-
nostic group (containing[10 patients), the
type of previous medication (PGA or beta-re-
ceptor blocker), the PGA molecule (latanoprost,
bimatoprost, travoprost, and tafluprost) for
those using a PGA at baseline, the reported
reasons for the PF tafluprost/timolol treatment
initiation, instillation time (morning or eve-
ning), and the presence or absence of dry eye
symptoms.
The clinical (ocular) signs were evaluated at
month 6 and were compared with the baseline
measures in all participants. Conjunctival
hyperemia and best corrected visual acuity
(BCVA) data reporting was mandatory at all
study visits. Visual acuity data were collected in
decimal, logMAR, or fraction (foot or meters)
scales (according to the sites’ practice) and were
converted to the decimal scale using the
appropriate conversion formulas [31]. Data
concerning corneal fluorescein staining (CFS)
were reported using the Oxford grading scale
(0–V grade dependent on intensity of punctate
staining across the cornea and conjunctiva)
[32]. Schirmer’s test, tear film breakup time
(TBUT), and conjunctival hyperemia were col-
lected at baseline and month 6; however, these
evaluations were allowed as optional tests at
interim visits. Conjunctival hyperemia was
evaluated using a four-grade severity scale
(none, mild, moderate, and severe).
The subjective symptoms were assessed at
each study visit. These comprised dry eye feel-
ing, irritation, itching, foreign body sensation,
and eye pain. Symptom severity was evaluated
using a four-grade scale (none, mild, moderate,
and severe). In addition, the investigator pro-
vided evaluation concerning the effectiveness
of the PF tafluprost/timolol FC therapy, the
clinical signs, and compliance to the study
medication compared with those for the prior
monotherapy using a three-grade scale: better
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than prior medication, same as prior medica-
tion, worse than prior medication. Patients
reported their assessment of tolerability con-
cerning PF tafluprost/timolol FC treatment on a
four-grade scale: very good, good, satisfactory,
poor.
Reported adverse events (AEs) and treat-
ment-related AEs were collected and docu-
mented at all visits and for the total study
period.
Statistical Analysis
ICON Plc (Dublin, Ireland) conducted all sta-
tistical analyses on behalf of the VISIONARY
study group. Data distribution was assessed
using Q–Q plots, histograms, and the Shapir-
o–Wilk or the Kolmogorov–Smirnov test, as
needed. For normally distributed data, the
mean and standard deviation (SD) are presented
and the paired t test was used for the compar-
isons. For data not normally distributed, the
median values and the interquartile range (IQR)
are shown and the Wilcoxon signed rank test
was used to assess change in median from
baseline. A linear mixed model was run with
IOP as the dependent variable and all time
points as independent variables to investigate
time-dependent IOP changes. Time-indepen-
dent comparisons between IOP values at each
study visit and the baseline value utilized a
paired t test, taking account of repeated mea-
sures. Change from baseline concerning CFS,
conjunctival hyperemia, and subjective symp-
toms was assessed using the Bhapkar test. The
Bhapkar test can be used in marginal homo-




In total, 721 participants were screened for
inclusion in the study and 713 were treated
with the PF tafluprost/timolol FC. Of these, 577
went on to complete the 6-month visit and
were included in the analysis (Fig. 1).
The baseline study population demographics
are shown in Table 1. Mean age (SD) was 67.8
(11.67) years (range 23.7–96.1 years), and 59.6%
of the final population were female. The most
common diagnostic groups comprised primary
open-angle glaucoma (POAG; 73.7%), OHT
(19.1%), pseudoexfoliative glaucoma (3.3%),
and normal tension glaucoma (2.3%). The
majority of the patients (72.1%) changed med-
ication from a PGA and 27.9% from beta-re-
ceptor blocker (timolol) therapy. At baseline,
the mean (SD) IOP was 21.55 (4.45) mmHg, the
mean (SD) CFS score was 0.76 (0.94), and med-
ian BCVA decimal score (IQR) was 0.9 (0.4).
IOP Change from Baseline
Concerning the primary endpoint, the absolute
mean IOP change at month 6 was statistically
significant (p\0.0001) (Table 2). Mean (SD)
IOP at month 6 was 15.8 mmHg (3.21). Mean
(SD) IOP reduction from baseline was 5.7 (4.11)
mmHg, representing an overall IOP reduction
of 24.9%. Statistically significant mean IOP
reductions from baseline were observed at each
of the interim study visits. At week 4, it was 5.4
(3.76) mmHg (23.7%; p\ 0.0001), and 5.9
(3.90) mmHg (25.6%; p\ 0.0001) at week 12. At
month 6, 69.2%, 53.6%, 40.0%, and 25.8% of
participants were responders based on C 20%,
C 25%, C 30%, and C 35% cutoff values for
change in mean IOP, respectively (Fig. 2).
Intraocular Pressure Subanalyses
The mean (SD) IOP at baseline was 21.5 (5.00)
mmHg, 22.3 (4.30) mmHg, 17.2 (2.68) mmHg,
and 21.7 (4.13) mmHg for patients diagnosed
with POAG, OHT, normal tension glaucoma,
and pseudoexfoliative glaucoma, respectively.
At month 6, respective relative IOP reductions
were 25.4%, 26.1%, 15.8%, and 17.6%. Differ-
ences between subgroups did not reach statis-
tical significance (p C 0.324).
At baseline, mean (SD) IOP was 21.9 (4.36)
mmHg and 21.4 (4.48) mmHg for the beta-re-
ceptor blocker and PGA users, respectively. At
month 6 IOP was 15.3 (3.10) mmHg in those
previously using a beta-receptor blocker, repre-
senting 6.6 (4.16) mmHg (28.5%) reduction
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from baseline (p\ 0.0001). In those treated
with a PGA, at month 6 IOP was 16.0 (3.23)
mmHg, representing 5.4 (4.04) mmHg (23.6%)
reduction (p\0.0001).
Prior to the study period, 64, 63, 87, and 201
patients were on bimatoprost, travoprost,
tafluprost, and latanoprost, respectively (for one
patient in the study population, the specific
PGA used was not recorded). The IOP at baseline
was 20.6 (4.39) mmHg, 20.0 (3.90) mmHg, 20.8
(3.29) mmHg, and 22.3 (4.93) mmHg for par-
ticipants treated with bimatoprost, travoprost,
tafluprost, and latanoprost, respectively. At
month 6, respective mean relative IOP reduc-
tions were 20.5%, 21.3%, 22.7%, and 25.9%
(p\ 0.0001 for all groups).
Of the 577 participants included in the
analysis, 469 individuals (81.3%) changed to PF
tafluprost/timolol FC treatment because of
uncontrolled IOP, and 106 (18.4%) were enrol-
led because of poor ocular tolerance on the
previous topical IOP-lowering medication (irre-
spective of the success of the IOP control). At
month 6, the mean relative IOP reduction was
26.6% for participants with insufficient IOP
control at baseline and 19.6% for those who did
not tolerate the previous topical medication
well (p\ 0.001).
At month 6, the instillation time (morning
versus evening) was recorded for 521 patients.
The mean (SD) relative IOP reduction from
baseline was 5.50 (4.14) mmHg (23.6%) for
those using morning instillation and 5.67 (3.99)
mmHg (24.7%) for evening instillation
(p = 0.5966). The mean relative IOP reduction
was not significantly different when comparing
those who reported no dry eye symptom at
baseline (n = 242) and those (n = 224) who
reported any severity of dry eye symptom
(24.9% vs 24.4% at month 6, p = 0.754).
Clinical Signs
Compared with the baseline value, the mean
(SD) CFS score was reduced at all study visits
during the PF tafluprost/timolol FC treatment
(Table 3). At baseline, the median (IQR) Schir-
mer’s test result was 10.0 (8.0). No statistically
significant change was seen concerning the
Schirmer’s test result during the study period
(p = 0.258). TBUT was 6.0 (5.0) s at baseline and
increased by an average 1 s value at all later
study visits (p = 0.0035). Statistically significant
increases in median TBUT were observed at each
study visit for participants on baseline PGA
monotherapy (p = 0.0012) but not in beta-re-
ceptor blocker users (p = 0.7490).
CFS scores of 0 or 1 were found in 188
(80.3%) patients at baseline and in 249 (91.5%)
at month 6 among those with data available.
The mean (SD) CFS score at month 6 was 0.47
(0.71), which was a statistically significant
Fig. 1 Patient disposition
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reduction compared with the mean baseline
value (0.76 [0.94]; p\0.0001) (Table 3). Over-
all, 32.7% of patients demonstrated a reduction
in the CFS score from baseline at month 6,
53.6% showed no change, and CFS was
increased in 13.6% of the patients.
Statistically significant reductions, compared
with baseline values, were found for conjuncti-
val hyperemia at week 4, week 12 and month 6
(p\ 0.0001 for each study visit). At month 6,
38.7% of the patients demonstrated reduction
in conjunctival hyperemia, 50.7% showed no
change, and 10.7% showed increased hyper-
emia. At baseline, conjunctival hyperemia was
mild or absent in 79.6% of participants on
latanoprost, 88.9% of those treated with taflu-
prost, 60.4% on bimatoprost, and 66.7% on
travoprost (Fig. 3). Moderate or severe hyper-
emia was reported for the remaining patients at
baseline. During the study period, conjunctival
hyperemia was significantly reduced at all study
visits for participants treated with each of the
baseline PGA monotherapies; latanoprost
(p\ 0.0001), tafluprost (p = 0.029), bimatoprost
(p\ 0.0001), and travoprost (p\0.0001). The
greatest improvement in conjunctival hyper-
emia severity was found in participants previ-
ously treated with bimatoprost or travoprost
([59.6% improvement at each study visit, for
both medications).
Subjective Symptoms
At baseline, subjective symptoms were generally
reported absent or of mild severity. This was the
case for more than 80% of patients concerning
dry eye, irritation, and itching, and more than
90% for individuals reporting of foreign body
sensation and eye pain. However, at month 6,
statistically significant reductions from baseline
were reported concerning severity of dry eye,
irritation, itching, and foreign body sensation
(p\ 0.001 for each category). Overall, dry eye
severity was reduced for 30.8% of the patients,
while 59.3% of the participants reported no
change, and 9.8% of the patients reported
increased severity. Severity of irritation was
reduced in 31.0% of the participants, while
61.0% experienced no change. Itching severity
was reduced in 26.6% of participants, while
62.8% reported no change. Foreign body sen-
sation was reduced in 23.0% of the participants,
69.9% reported no change, and an increase in










Pseudoexfoliative glaucoma 19 (3.3)
Normal tension glaucoma 13 (2.3)
Pigmentary glaucoma 5 (0.9)
Other glaucoma 5 (0.9)
Study eye, n (%)
Right 363 (62.9)
Left 214 (37.1)
Previous treatment, n (%)
Beta-blocker therapy 161 (27.9)
PGA therapy 416 (72.1)
IOP at baseline, mmHg (mean ± SD) 21.55 ± 4.45
CFS score (Oxford grade scale)
(mean ± SD) (n = 238)
0.76 ± 0.94
BCVA decimal score, median (IQR)
(n = 461)
0.9 (0.40)
Schirmer’s test, median (IQR) (n = 124) 10.0 (8.00)
TBUT seconds, median (IQR) (n = 176) 6.0 (5.00)
SD standard deviation, POAG primary open-angle glau-
coma, OHT ocular hypertension, PGA prostaglandin
analogue, IOP intraocular pressure, CFS corneal fluores-
cein staining, BCVA best corrected visual acuity, TBUT
tear breakup time, IQR interquartile range
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severity was reported by 7.5% of the patients.
No significant change was found concerning
eye pain severity at month 6 (p = 0.058); 7.8%
of the participants reported pain reduction,
88.9% experienced no change, and 3.3%
reported that the pain increased.
Physician Assessments
On the basis of clinical evaluation, most inves-
tigators (84.7%) considered IOP control more
effective with PF tafluprost/timolol FC treat-
ment than with the previous medication, at
month 6. The investigators also reported
reduced ocular signs at month 6 in 63.6% of the
participants, compared with the previous med-
ication. Overall, compliance to the PF
tafluprost/timolol FC treatment was perceived
to be greater (48.9%) or comparable (46.0%)
with that on the previous medications, when
evaluated by the investigators.
Patient Assessment
The majority of patients reported that the tol-
erability of the PF tafluprost/timolol FC treat-
ment was good or very good at week 4 (87.9%),
week 12 (92.4%), and month 6 (91.4%).
Table 2 Intraocular pressure change from baseline at week 4, week 12, and month 6
Visit N Mean (SD)
IOP (mmHg)
Mean (SD) reduction in
IOP from baseline (mmHg)
Mean percentage reduction
in IOP from baseline
p value#
Baseline 577 21.5 (4.45)
Week 4 541 16.2 (3.28) 5.4 (3.76) 23.7 \ 0.0001
Week 12 503 15.7 (3.98) 5.9 (3.90) 25.6 \ 0.0001
Month 6 577 15.8 (3.21) 5.7 (4.11) 24.9 \ 0.0001
IOP intraocular pressure
# Significance testing using two-sided paired t test for change in mean IOP from baseline to week 4, week 12, and month 6
Table 3 Cornea fluorescein staining score and its change during the study period
Mean change from baseline
N Mean (SD) N Mean (SD) p value*
Baseline 234 0.76 (0.94)
Week 4 (± 7 days) 243 0.55 (0.76) 202 0.19 (0.75)1 0.0003
Week 12 (± 7 days) 226 0.54 (0.78) 189 0.21 (0.93)2 0.0020
Month 6 (± 45 days) 272 0.47 (0.71) 220 0.27 (0.95)3 \ 0.0001
Change in median CFS at baseline and respective time point along with Wilcoxon signed rank test p value were
1p = 0.0003; 2p = 0.0023; 3p\ 0.0001
CFS corneal fluorescein staining
Fig. 2 Percentage of responders according to different
intraocular pressure reduction cutoff values at month 6.
IOP intraocular pressure
Adv Ther (2020) 37:1436–1451 1443
Reasons for Discontinuation
Overall, 98 patients (17.0%) discontinued the
PF tafluprost/timolol FC treatment during the
6-month study period. The reported reasons of
treatment discontinuation comprised insuffi-
cient IOP control for 2 patients, poor local tol-
erance for 12 patients, poor compliance for 4
patients, and ‘‘other reasons’’ for 13 patients.
Data were missing for the remaining 67
patients.
Safety
For the 577 individuals included in the safety
analysis, 129 AEs were reported by 99 (17.2%)
patients during the 6-month study period. The
majority of the AEs (94.6%) were reported as
non-serious, and 69 (53.5%) were considered to
be treatment-related (Table 4). One of these was
serious (status asthmaticus). Most AEs (93.0%)
were mild to moderate in severity, and the
majority (71.3%) had resolved or were resolving
at the point of data cutoff.
DISCUSSION
In the current 6-month, observational, multi-
center, European, prospective clinical investi-
gation completed by 577 patients with OAG
and OHT, clinical experience with changing
topical medication from a PGA or a beta-recep-
tor blocker to the PF tafluprost/timolol FC was
analyzed for IOP change, objective clinical
ocular surface signs, the participants’ subjective
symptoms, and patient- and ophthalmologist-
indicated satisfaction with the study medica-
tion. In this real-world study, no washout per-
iod between the prior and study medication was
used, even when the prior medication was not
optimally tolerated and patients with ocular
Fig. 3 Change in conjunctival hyperemia severity accord-
ing to the previous prostaglandin analogue treatment.
Severity of conjunctival hyperemia at each study visit for
those previously treated with a latanoprost, b tafluprost,
c bimatoprost, or d travoprost
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surface abnormalities were included. Thus, in
contrast to the randomized clinical trials previ-
ously conducted on the PF tafluprost/timolol
FC, in which a complete washout period was
used and the patients had to be free from ocular
surface abnormalities, in the current investiga-
tion we mirrored real-life clinical practice,
which is particularly important to all ophthal-
mologists [10, 14–16].
Regarding IOP, we found a statistically and
clinically significant, consistent IOP reduction
at all time points including the week 4 and 12
visits, and at month 6, which was the primary
endpoint of the investigation. At month 6, for
the total population, the mean IOP reduction
compared to the under-treatment baseline value
was 5.7 mmHg (24.9%). Considering that the
mean baseline IOP was 21.55 mmHg, this
almost 25% IOP reduction is favorable since IOP
reduction achieved with any PGA/timolol FC
strongly depends on the baseline IOP, which
was relatively low in our population [34]. The
mean IOP reductions found in the week 4 and
week 12 visits were similar, which suggests that
ophthalmologists can expect a meaningful IOP
reduction shortly after the change to the
tafluprost/timolol FC from a PGA or beta-re-
ceptor blocker monotherapy. Furthermore, the
Table 4 Treatment related adverse events reported during
the study period
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responder rates were also favorable. At month 6,
almost 70% of the patients had an IOP reduc-
tion over 20%, and 53.6% and 40.0% of the
patients experienced an IOP reduction over 25%
and 30%, respectively. In almost 26% of the
participants the relative IOP reduction exceeded
35%. These results suggest that there is high
probability of reaching a clinically satisfactory
IOP reduction with changing PGA or beta-re-
ceptor blocker medication for the PF
tafluprost/timolol FC in OAG and OHT.
It is also of clinical importance that mean-
ingful IOP reduction was achieved both in OHT
and all types of glaucoma represented in the
investigation (POAG, pseudoexfoliative glau-
coma, and normal tension glaucoma). For all
these groups the relative IOP reduction ranged
between 17.6% (normal tension glaucoma) and
25.4% (POAG) with no statistically significant
difference between the IOP reductions in the
various disease categories. Another clinically
important point is that the IOP reduction in
previous beta-receptor blocker users (28.5%)
was somewhat greater than that in previous
PGA users (23.6%), even if their baseline under-
treatment IOP was similar (21.4 and
21.9 mmHg, respectively). A similar IOP reduc-
tion was found for all PGAs used before the
study (20.5–25.9%). This suggests that patients
on all currently available PGA monotherapies
benefit from changing to tafluprost/timolol FC,
in terms of IOP reduction. Not unexpectedly,
we found that those patients who were enrolled
in the investigation because of insufficient IOP
control on the previous monotherapy showed
significantly greater IOP reduction than those
participants who entered the study for poor
tolerance of the previous medication (26.6% vs.
19.6%). At the same time, however, this finding
also shows that even those patients who are
considered as being controlled for IOP with a
PGA or a beta-receptor blocker monotherapy
can gain an almost 20% further IOP reduction
by changing to the PF tafluprost/timolol FC.
The similarity of IOP reduction of participants
with or without dry eye symptoms at baseline
(24.9% and 24.4% at month 6) also supports
that the PF tafluprost/timolol FC cannot be
considered as a glaucoma medication restricted
only for dry eye or OSD patients. Finally,
another important result of our study is that
there was no difference in mean IOP reduction
between those who instilled the tafluprost/ti-
molol FC in the morning and those who
instilled it in the evening (5.50 vs. 5.67 mmHg).
This finding is of clinical importance since it
shows that, in contrast to the controlled clinical
investigations in which evening instillation of
tafluprost/timolol FC provided somewhat lower
diurnal IOP, in real-life conditions ophthal-
mologists can accept their patients’ preference
on the instillation time [10]. This may support
adherence and does not considerably influence
the achieved IOP reduction.
Regarding ocular signs and symptoms, the
change to PF tafluprost/timolol FC resulted in
improvement in most of the measures used in
our study. At month 6, the mean CFS score
decreased significantly for the total study pop-
ulation. Almost one-third of the patients expe-
rienced a reduced CFS score. For the previous
PGA users, the CFS score decreased significantly
in all visits, compared to the baseline value. For
the total population the mean conjunctival
hyperemia score decreased significantly in all
visits compared to the baseline score, and an
improvement was seen in 38.7% of the patients
in the month 6 visit. In the previous PGA users a
highly significant reduction of hyperemia score
was found for each of the four PGAs. The largest
improvements were seen for the previous
bimatoprost and travoprost users.
In all but one of the subjective symptom
categories examined (dry eye feeling, irritation,
itching, and foreign body sensation) a statisti-
cally and clinically significant improvement
was reported at month 6; an improvement was
found in 31.0% of the patients for dry eye
feeling, 26.6% for eye itching, and 23.0% for
foreign body sensation. No change in the eye
pain score was found. These results show that
many patients with glaucoma experienced
considerable improvement of ocular tolerance
on the PF tafluprost/timolol FC, even if their
ocular surface-related complaints were mild or
not obvious at baseline.
The evaluation of the study medication was
positive by both the treating ophthalmologists
and the study participants. At month 6, oph-
thalmologists considered IOP as better
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controlled with the PF tafluprost/timolol FC
medication than with the previous monother-
apy in 84.7% and classified the ocular signs as
reduced compared to the baseline in 63.6%.
They also considered compliance to the study
medication better than to the previous
monotherapy in almost half of the patients,
while they indicated that the compliance was
similar to that on the pre-study eye drop for
46.0% of the participants. The patient-reported
tolerability was similarly favorable: the fre-
quency of good or very good tolerability cate-
gory ranged between 87.9% and 92.4% in all
study visits.
Early termination was recorded in 98
patients (17.0%). As a result of the observational
nature of the investigation the reason for study
discontinuation was not clarified for 67
patients. The known reasons for study discon-
tinuation were related to insufficient IOP con-
trol (2 patients), poor ocular tolerance (12
patients), and poor compliance (4 patients).
Thirteen patients withdrew from the study for
‘‘other reasons’’. Of the 129 AEs reported by 99
patients, 69 were considered as treatment-re-
lated. Ninety-three percent of the AEs were mild
and 73.1% had recovered or were recovering
when the study was completed. Only one seri-
ous AE (status asthmaticus) was recorded, which
probably could have been prevented by con-
sidering the contraindications of timolol, the
beta-receptor blocker part of the study medica-
tion. The above safety data show that in general
PF tafluprost/timolol FC was well tolerated.
Our study has limitations. It was an obser-
vational study; therefore, relatively many par-
ticipants left the study without letting the
investigators know about the reason for their
early termination. The participants represented
various areas of Europe, but their ethnicity was
not investigated. Therefore, caution is needed
when conclusions from our data are applied to
patients with non-European origin. Since we
investigated adult patients with OAG and OHT
our results cannot be applied to angle-closure
glaucoma and childhood glaucomas. We did
not investigate switching to PF tafluprost/ti-
molol FC from combined topical medication;
therefore, our IOP results may not be repro-
duced when patients are switched from a fixed
or unfixed topical combined medication regi-
men to PF tafluprost/timolol FC.
CONCLUSION
In our large multicenter observational study PF
tafluprost/timolol FC demonstrated statistically
and clinically significant IOP reductions in
patients with OAG and OHT who were either
insufficiently controlled on a PGA or beta-re-
ceptor blocker monotherapy, or did not tolerate
these medications. The full IOP reduction was
present already at the week 4 visit, and the
efficacy was maintained over the total 6-month
study period. The severity of most clinical signs
and subjective symptoms decreased signifi-
cantly compared to that on the previous treat-
ment, and in general the PF tafluprost/timolol
FC was well tolerated.
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7. Holló G, Katsanos A, Boboridis KG, Irkec M, Konstas
AG. Preservative-free prostaglandin analogs and
prostaglandin/timolol fixed combinations in the
treatment of glaucoma: efficacy, safety and poten-
tial advantages. Drugs. 2018;78(1):39–64.
8. Tabet R, Stewart WC, Feldman R, Konstas AG. A
review of additivity to prostaglandin analogs: fixed
and unfixed combinations. Surv Ophthalmol.
2008;53(1):S85–92.
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